Drug major Sun Pharma is planning to increase the share of complex generics and specialty products to its overall business portfolio.
Israel Makov, Chairman of Sun Pharmaceutical Industries, said, "While our specialty business will become an additional engine of growth for us, we will continue our relentless focus on the generics business and our attempt will be to find ways to grow the generics business faster than respective markets."
With this expansion, the company will drive a stable and consistent growth in cash flows.
"We are targeting to increase the share of complex generics and specialty products to our overall business in the coming years," Makov added.
The specialty portfolio of Sun Pharma is targeting dermatology, ophthalmic, oncology and CNS segments.
Makov further stated, "The specialty initiative will entail incurring up-front cost and investments for long-term benefits."